康拓医疗(688314) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥55,289,121.77, representing a year-over-year increase of 26.92%[5] - The net profit attributable to shareholders for Q3 2021 was ¥27,175,982.55, reflecting a 50.52% increase compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥22,599,759.69, showing a significant increase of 99.49% year-over-year[5] - Total revenue for the first three quarters of 2021 reached ¥151,054,585.32, a 33.6% increase compared to ¥113,069,140.66 in the same period of 2020[24] - Net profit for the third quarter of 2021 was ¥61,511,761.41, compared to ¥40,365,225.30 in the same quarter of 2020, representing a 52.3% increase[25] - The net profit attributable to the parent company shareholders for Q3 2021 was ¥61,904,233.22, an increase from ¥41,485,401.32 in Q3 2020, representing a growth of approximately 49.3%[26] - The total comprehensive income attributable to the parent company for Q3 2021 was ¥61,961,081.14, compared to ¥41,215,914.54 in Q3 2020, reflecting a growth of 50.5%[26] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥541,783,624.50, which is an 85.86% increase compared to the end of the previous year[6] - The total assets of the company as of the end of the third quarter of 2021 amounted to ¥541,783,624.50, significantly higher than ¥291,506,419.87 at the end of the same period in 2020[20] - Current assets totaled ¥347,014,032.66, compared to ¥143,318,132.92 in the previous year, indicating a substantial growth[20] - The company's total liabilities reached ¥59,635,877.98, up from ¥48,458,340.54 in the same period last year[21] - The equity attributable to shareholders increased by 97.94% year-over-year, amounting to ¥484,025,720.10[6] - The equity attributable to shareholders increased to ¥484,025,720.10 from ¥244,534,057.40 year-over-year[21] Earnings and Cash Flow - The basic earnings per share for Q3 2021 was ¥0.47, a 14.63% increase compared to the same period last year[6] - The basic and diluted earnings per share for Q3 2021 were both ¥1.24, compared to ¥0.95 in Q3 2020, indicating a year-over-year increase of 30.3%[27] - Cash flow from operating activities for the first three quarters of 2021 was ¥68,132,297.09, up from ¥38,624,149.10 in the same period of 2020, reflecting a growth of 76.4%[27] - Total cash inflow from operating activities was ¥188,256,785.37, compared to ¥137,841,460.37 in the previous year, marking an increase of 36.5%[27] - The net cash flow from financing activities for Q3 2021 was ¥183,738,361.81, a significant improvement from a net outflow of ¥3,919,836.68 in Q3 2020[28] Research and Development - Research and development expenses totaled ¥2,473,667.20 for Q3 2021, which is a decrease of 19.89% compared to the same period last year[6] - The proportion of R&D expenses to operating revenue was 4.47%, down by 2.62 percentage points year-over-year[6] - Research and development expenses for the third quarter of 2021 were ¥8,228,680.85, slightly down from ¥8,301,936.76 in the previous year[25] - The important research product, 3D printed PEEK craniofacial system, is undergoing clinical trials in five hospitals, with smooth progress in its development registration[16] Production and Operations - The new factory project for the production and research of three types of implantable medical devices is under orderly construction, with the main production and office areas completed[15] - The company has obtained the medical device production license for the new factory, which is expected to enhance production capacity and efficiency[15] - The company plans to complete the relocation to the new factory and related license changes by the end of the year[15] Revenue Breakdown - The company achieved a main business revenue of 146.91 million RMB, a year-on-year increase of 35.07%, and a net profit attributable to shareholders of 61.90 million RMB, up 49.22% year-on-year[15] - Revenue from PEEK material repair products reached 58.21 million RMB, a year-on-year growth of 70.58%[15] - The PEEK material skull fixation products generated revenue of 30.15 million RMB, reflecting a 23.80% increase compared to the same period last year[15] - The revenue from titanium skull repair products was 13.50 million RMB, showing a year-on-year growth of 16.84%[15] - The revenue from titanium skull fixation products was 38.46 million RMB, with a year-on-year increase of 5.86%[15] - The revenue from PEEK material sternum fixation system reached 3.19 million RMB, a significant increase of 1560.52% year-on-year[15]